EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
A legfontosabb adatok
- Hol
- Hamburg (Németország)A helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan gyermekeket és fiatalokat keres, akiknél 2000 és 2026. 12. 31. között juvenilis eozinofil fasciitist diagnosztizáltak. Legalább 6 hónapos követési idejük kell legyen.
- Életkor
- A diagnóziskor 18 évnél fiatalabb.
- Nem
- Nemtől függetlenül bárki részt vehet.
- A betegség stádiuma
- Juvenilis kezdetű eozinofil fasciitis diagnózisa 2000 és 2026. 12. 31. között.
A részvétel fő kizáró okai
- A diagnóziskor 18 éves vagy idősebb
- 6 hónapnál rövidebb követési idő
- Nem kíván részt venni a vizsgálatban
Gépi kiolvasás: 2026. november 9.
Helyszínek itt: Németország
- Hamburger Zentrum für Kinder- und Jugendrheumatologie -Hamburg, NémetországToborzás még nem indult
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
A vizsgálat adatai
- Ki végzi
- Meyer Children's Hospital IRCCS
- Azonosító
- NCT07348263
- A regiszteradat frissítve
- 2026. március 11.
- Eredeti leírás
Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.A teljes eredeti leírásKevesebb
International Multicentre Cohort Study on Clinical Manifestations and Response to Therapy in Juvenile Onset Eosinophilic Fasciitis
Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.
Kizáró feltételek: Age ≥18 years at diagnosis; Unwilling to participate into the study; A follow-up period < 6 months.
Inclusion criterai:; All patients diagnosed from 2000 to 31/12/2026; minimum follow-up 6 months; Age <18 years at diagnosis; All patients whose informed consent is collected in accordance with current local legislation will also be considered enrollable.